Latest revenue
$16.1M
as of 2026-03-31
Latest net income
$-8.7M
as of 2026-03-31
Net margin
-54.0%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $329.2M
- Enterprise value
- $329.2M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $17.19
- 52-wk low
- $8.50
- Beta
- —
- Shares out
- 27.2M
5-year trend
What this company does
Item 1. Business. Overview We are a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions with a focus on becoming the standard of care for spine fusion surgery. Our mission is to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. The aprevo Technology Platform was designed to address the limitations of traditional lumbar and cervical spine fusion surgery, aiming to optimize patient outcomes and reduce the need for revision surgeries. 2 Our technology is powered by AI-enabled, outcome-based algorithms that provide personalized surgical plans for spine fusion. The aprevo surgical kit delivered to customers…
AI summary unavailable — showing raw filing excerpt
Generated from CARL's filing dated 2026-02-25
Key risks
Item 1A. Risk Factors. Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this Annual Report, including our financial statements and the related notes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” before deciding whether to invest in our common stock. The occurrence of any of the events or developments described below could have a material adverse effect on our business, financial condition, results of operations, and prospects. In such an event, the market price of our common stock could decline, and you may lose all or part of your…
AI summary unavailable — showing raw filing excerpt
Generated from CARL's filing dated 2026-02-25
Profitability
Gross margin
75.3%
2.0%Operating margin
-60.5%
31.8%Net margin
-58.7%
34.3%Return on equity
-30.0%
187.3%Return on assets
-22.8%
51.3%Leverage
Debt / equity
0.32×
118.2%Long-term debt / equity
0.16×
171.1%Debt / assets
24.0%
89.8%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $16.1M | +58.2% | $-8.7M | -51.8% | -54.0% |
Q4 2025 2025-12-31 | $15.2M | — | $-8.6M | — | -56.8% |
Q3 2025 2025-09-30 | $13.1M | +98.4% | $-8.5M | -9.1% | -65.2% |
Q2 2025 2025-06-30 | $12.1M | +98.7% | $-6.8M | -7.8% | -56.0% |
Q1 2025 2025-03-31 | $10.2M | — | $-5.7M | — | -56.2% |
Q3 2024 2024-09-30 | $6.6M | — | $-7.8M | — | -118.6% |
Q2 2024 2024-06-30 | $6.1M | — | $-6.3M | — | -103.2% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Surgical & Medical Instruments & Apparatus · SIC 3841
Your notes
Keep private notes on CARL — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$48.1M
Insider selling
$2.6M
Net activity
+$45.5M
Distinct insiders
6
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns CARL
Institutional value
$12.6M
Total shares held
1.4M
Distinct holders
33
-23 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 446.9K | $4.0M | +19.4K (+4.5%) | Added |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 276.1K | $2.5M | — | New |
| 3 | KCM Capital Inc | 200.0K | $1.8M | — | New |
| 4 | Russell Investments Group, Ltd. | 159.3K | $1.4M | -947 (-0.6%) | Trimmed |
| 5 | KORNITZER CAPITAL MANAGEMENT INC /KS | 53.4K | $483.6K | -1.8K (-3.3%) | Trimmed |
| 6 | VANGUARD PORTFOLIO MANAGEMENT LLC | 47.6K | $431.2K | — | New |
| 7 | VANGUARD FIDUCIARY TRUST CO | 45.4K | $410.9K | — | New |
| 8 | WESBANCO BANK INC | 37.0K | $334.9K | +0 (+0.0%) | No change |
| 9 | Boston Partners | 25.2K | $228.1K | -899 (-3.4%) | Trimmed |
| 10 | TD Waterhouse Canada Inc. | 20.0K | $192.0K | -155.4K (-88.6%) | Trimmed |
| 11 | JANE STREET GROUP, LLC | 15.0K | $136.1K | — | New |
| 12 | Bank of New York Mellon Corp | 13.1K | $118.6K | +1 (+0.0%) | Added |
| 13 | Board of Trustees of The Leland Stanford Junior University | 12.5K | $113.3K | -12.5K (-50.0%) | Trimmed |
| 14 | UBS Group AG | 10.3K | $93.2K | -383 (-3.6%) | Trimmed |
| 15 | DEUTSCHE BANK AG\ | 9.8K | $89.0K | +0 (+0.0%) | No change |
| 16 | RHUMBLINE ADVISERS | 5.2K | $46.9K | +762 (+17.2%) | Added |
| 17 | JPMORGAN CHASE & CO | 5.1K | $46.7K | +1.8K (+55.8%) | Added |
| 18 | Vanguard Global Advisers, LLC | 3.6K | $32.4K | — | New |
| 19 | WELLS FARGO & COMPANY/MN | 3.3K | $30.2K | -4.5K (-57.5%) | Trimmed |
| 20 | BNP PARIBAS FINANCIAL MARKETS | 2.6K | $23.2K | +417 (+19.4%) | Added |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once CARL's latest filing finishes processing.